In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Banner Year For Pharma: M&A Tops 2009 Merger Mania

Executive Summary

Fourteen deals have been signed so far in 2014 with an up-front value of $1 billion or more. The standout year for pharma M&A is already more valuable than 2009, the year Pfizer bought Wyeth and Merck acquired Schering-Plough.

You may also be interested in...



2016 Pharma Dealmaking: Waiting On The High-Value Deals

Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.

Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes

The year was marked by record levels of biopharma M&A activity and a strong IPO market. Measures designed to deliver early access to new medicines continued to advance on both sides of the Atlantic, while pricing came in for renewed attention as new, highly effective but extremely expensive products reached the market.

Biopharma Dealmaking Quarterly Statistics, Q3 2014

Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel